BST-02

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameBST-02
Drug Alias NameBST-02BST02
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating LymphocytesCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionT lymphocyte replacementsGlypican-3 modulators
TargetsGlypican-3
Therapy Area/IndicationsLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBiosyngen Pte Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangzhou Baiji Biopharmaceutical Co LtdBiosyngen Pte Ltd
Inactive CompaniesN/A
Active IndicationsLiver Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A